博鳌亚洲论坛全球健康论坛2025北京会议于近日举办，论坛聚焦生物医药行业，举办了以"生物医药行业加速从'量变'到'质变'"为主题的分论坛。论坛上众 多专家学者深入探讨了全球生物医药行业的未来走向，剖析了行业即将面临的挑战与风险，同时也展望了潜藏的机遇和有望取得的成果，其中，细胞疗法、 基因编辑等技术的多点突破成为焦点。 美国贝克曼库尔特医学诊断全球副总裁兼中国区总经理陈淮表示，人工智能（AI）技术与生物技术正实现深度融合。AI技术已在多个领域得到广泛应用， 以贝克曼库尔特为例，作为体外诊断试剂领域的从业者，核心任务之一是寻找生物标志物。以往采用传统技术筛选生物标志物，周期约为五年；而借助AI 技术，整个开发周期可缩短至18个月，效率提升显著。 在行业内，类似的成功案例还有很多，例如以AI为驱动的癌症疫苗研发，近年来进展迅猛，取得了良好的发展成果。陈淮表示，细胞疗法及CRISPR基因编 辑技术的应用日益广泛。例如，CAR-T、TCR-T等免疫疗法已在多个领域得到应用，尤其在血液肿瘤治疗中成效显著，目前正逐步向实体肿瘤治疗领域拓 展；CRISPR基因编辑技术则在罕见病治疗方面发挥着重要作用，这些都是技术层面的突出 ...

Core Insights - Evaxion A/S announces key executive management changes to enhance value from its AI-Immunology™ platform and pipeline [1] - Christian Kanstrup steps down as CEO, with Dr. Birgitte Rønø appointed as interim CEO while a search for a new permanent CEO begins [2][5] - Thomas Schmidt is appointed as the permanent CFO, having previously served as interim CFO since November 2024 [3][4] Management Changes - The company is actively searching for a new CEO with a strong focus on business development and transformational leadership [5] - Dr. Rønø has been with Evaxion since 2017 and has significant experience in scientific and strategic roles [2] - Thomas Schmidt's financial expertise is expected to support the company's operations and leadership during this transition [4] Company Overview - Evaxion is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop vaccines targeting cancer, bacterial diseases, and viral infections [7] - The company has a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline for infectious diseases, addressing high unmet medical needs [7]

李泽钜提到，目前公司正在开展多个癌症疫苗研发项目，其中包括上个月公布的TROP2癌症疫苗项 目。TROP2是一种在多类癌症中有过度表现的蛋白，常见于三阴性乳癌、肺癌、胃癌、结直肠癌、胰 脏癌、前列腺癌及卵巢癌。公司的TROP2融合蛋白和circRNA癌症疫苗在4项临床前研究中被发现能大 幅度抑制肿瘤生长，于乳癌和结直肠癌小鼠模型中显示 100%的肿瘤生长抑制。估计大约需要24-30个月 的时间便能开始I/II期临床试验。 智通财经APP获悉，长江生命科技(00775)主席李泽钜近日在股东周年大会中表示，生物科技研究是属于 一个高回报、高风险的行业。如果研究成功的话，只需一只产品，它的价值有机会可以高过很多上市基 建甚至地产公司。如果买股票纯粹为收息，可能买基建或收租股较适合。其认为，如果公司有一个全面 性投资组合，将一部分资金投放于这类高值博率投资上是正确的。 至于是否分拆其生物制药部门在香港上市，李泽钜表示，公司会不断评估策略机遇，以提高股东价值并 优化公司业务结构。目前，公司没有任何需要发布的公告，并将随时向市场通报任何重大进展。针对是 否有意通过配股或者可转换债券集资以帮助研发，他回应称，公司尚未发布任 ...

Group 1 - Jiangsu Life Science Technology (00775.HK) recently announced promising early results from preclinical laboratory tests of its novel cancer vaccine targeting trophoblast cell surface antigen 2 (TROP2) [1] - The TROP2 vaccine has shown significant tumor growth inhibition in preclinical studies, with four out of five studies demonstrating 100% tumor growth suppression and one study showing approximately 80% suppression in over 170 mice [1] - The TROP2 vaccine is expected to become the first curative therapy for high-incidence cancers in Asia, addressing urgent clinical needs and potentially covering multiple cancer types such as lung and pancreatic cancer [1] Group 2 - The company has multiple clinical-stage medical research projects and its R&D product line is considered severely undervalued, with potential for value release and substantial performance contributions [2] - The company reported a nearly 60% year-on-year increase in clinical trial and laboratory expenses, reaching HKD 161 million in 2024, indicating a strong commitment to R&D [2] - The company is exploring various strategic options, including strategic partnerships, joint ventures, business spin-offs, and mergers, to maximize shareholder value and enhance its capital acquisition channels [2]

Core Insights - The company, Changjiang Life Sciences (00775), will present the latest preclinical research data on its cancer vaccine at the AACR 2025 Annual Meeting in Chicago [1][2] - The cancer vaccine targets several proteins, including Preferentially Expressed Antigen in Melanoma (PRAME), programmed cell death-ligand 1 (PD-L1), B7 homolog 3 (B7-H3), and Claudin 6 [1][2] - The company is satisfied with the preclinical efficacy results of the cancer vaccines targeting these proteins and aims to advance them to clinical stages [2] Research and Development - PRAME is a protein highly expressed in melanoma, liver cancer, and blood cancers [1] - PD-L1 is a crucial immune checkpoint protein that inhibits T cell activation in the tumor microenvironment [1] - B7-H3 is another immune checkpoint protein that regulates T cell responses and is often overexpressed in cancers [2] - Claudin 6 is a tight junction protein that regulates epithelial barrier integrity and is overexpressed in breast cancer, lung cancer, and endometrial cancer [2] AI-Driven Vaccine Design - The company will showcase two panels at the AACR 2025 Annual Meeting in collaboration with research partners, highlighting an AI-driven platform for designing cancer vaccines [2] - The use of the AI platform is expected to enhance the immunogenicity and efficacy of the designed vaccines [2] Clinical Trials - The company is accelerating its cancer vaccine research, with multiple therapeutic cancer vaccines at various stages, including clinical and preclinical phases [2] - The cancer vaccine seviprotimut-L is currently in the final research phase, being tested as an adjuvant therapy for melanoma patients post-surgery [2]

Group 1 - The company, Changjiang Life Science Technology, has announced promising early results from preclinical laboratory tests of a novel cancer vaccine targeting TROP2, a cell surface glycoprotein overexpressed in various cancers such as breast, lung, pancreatic, and colorectal cancers [1] - TROP2 plays a critical role in cell proliferation, metastasis, and invasion, making it a potential therapeutic target in oncology due to its high expression in cancer cells and minimal presence in normal tissues [1] - The TROP2 cancer vaccine candidate utilizes innovative circular RNA (circRNA) and fusion protein constructs, demonstrating significant tumor growth inhibition in preclinical studies involving over 170 mice, with complete tumor growth suppression observed in all breast cancer studies [1] Group 2 - The incidence of breast cancer, particularly triple-negative breast cancer (TNBC), is rising sharply in Asia, affecting many young women, with higher rates and severity compared to Western countries [2] - The company believes that the TROP2 cancer vaccine shows unprecedented anti-cancer efficacy based on mouse studies and aims to advance it to clinical research stages to provide new treatment options for patients [2] - The company has filed patent applications for the circRNA and fusion protein TROP2 cancer vaccine with the Hong Kong Intellectual Property Department and a provisional patent application with the U.S. Patent and Trademark Office [2] Group 3 - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on April 11, 2025 [3]